- Public Comps
- Biohit
Biohit Valuation Multiples
Discover revenue and EBITDA valuation multiples for Biohit and similar public comparables like Episurf Medical, OssDsign, Cyclopharm, Singular Health and more.
Biohit Overview
About Biohit
Biohit Oyj is a biotechnology company. It manufactures products that bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry. Biohit's product portfolio consists of diagnostic tests, analysis systems, products that bind carcinogenic acetaldehyde into harmless compounds and monoclonal antibodies and service laboratory operations.
Founded
1988
HQ

Employees
46
Website
Financials (FY)
EV
$43M
Valuation Multiples
Start free trialBiohit Financials
Biohit reported last fiscal year revenue of $18M and EBITDA of $4M.
In the same fiscal year, Biohit generated $12M in gross profit, $4M in EBITDA, and $3M in net income.
Revenue (LTM)
Biohit P&L
In the most recent fiscal year, Biohit reported revenue of $18M and EBITDA of $4M.
Biohit is profitable as of last fiscal year, with gross margin of 68%, EBITDA margin of 21%, and net margin of 17%.
Financial data powered by Morningstar, Inc.
Biohit Stock Performance
Biohit has current market cap of $47M, and enterprise value of $43M.
Market Cap Evolution
Biohit's stock price is $3.06.
Biohit share price increased by 1.1% in the last 30 days, and decreased by 13.0% in the last year.
Biohit has an EPS (earnings per share) of $0.21.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $43M | $47M | 0.0% | 1.1% | 3.1% | -13.0% | $0.21 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBiohit Valuation Multiples
Biohit trades at 2.4x EV/Revenue multiple, and 11.2x EV/EBITDA.
EV / Revenue (LTM)
Biohit Financial Valuation Multiples
As of July 13, 2026, Biohit has market cap of $47M and EV of $43M.
Biohit has a P/E ratio of 14.9x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Biohit Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Biohit Margins & Growth Rates
Biohit grew revenue by 8% but EBITDA decreased by 7% in the last fiscal year.
In the most recent fiscal year, Biohit reported gross margin of 68%, EBITDA margin of 21%, and net margin of 17%.
Biohit Margins
Biohit Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Biohit Operational KPIs
Biohit's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Biohit's Rule of 40 is 26% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Biohit's Rule of X is 38% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Biohit Competitors
Biohit competitors include Episurf Medical, OssDsign, Cyclopharm, Singular Health, Anatolia Geneworks, Tobii, Ortoma, Sensus Healthcare, Elutia and Myomo.
Most Biohit public comparables operate across Life Sciences Tools, Medical Devices, BioTech, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 32.6x | - | (8.9x) | - | |||
| 1.5x | 1.6x | (7.1x) | (6.4x) | |||
| 2.0x | 1.9x | (4.2x) | (4.1x) | |||
| 280.9x | - | (9.3x) | - | |||
| 3.5x | - | (26.3x) | - | |||
| 1.1x | 1.2x | 3.1x | 4.1x | |||
| 5.5x | 5.7x | (88.2x) | (22.6x) | |||
| 1.2x | 1.3x | (3.3x) | (3.2x) | |||
This data is available for Pro users. Sign up to see all Biohit competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Biohit
| When was Biohit founded? | Biohit was founded in 1988. |
| Where is Biohit headquartered? | Biohit is headquartered in Finland. |
| How many employees does Biohit have? | As of today, Biohit has over 46 employees. |
| Is Biohit publicly listed? | Yes, Biohit is a public company listed on Nasdaq Helsinki. |
| What is the stock symbol of Biohit? | Biohit trades under BIOBV ticker. |
| When did Biohit go public? | Biohit went public in 1999. |
| Who are competitors of Biohit? | Biohit main competitors include Episurf Medical, OssDsign, Cyclopharm, Singular Health, Anatolia Geneworks, Tobii, Ortoma, Sensus Healthcare, Elutia, Myomo. |
| What is the current market cap of Biohit? | Biohit's current market cap is $47M. |
| What is the current revenue of Biohit? | Biohit's last fiscal year revenue is $18M. |
| What is the current revenue growth of Biohit? | Biohit revenue growth (vs. last FY) is 8%. |
| What is the current EV/Revenue multiple of Biohit? | Current revenue multiple of Biohit is 2.4x. |
| Is Biohit profitable? | No, Biohit is not profitable. |
| How many companies Biohit has acquired to date? | Biohit hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Biohit has invested to date? | Biohit hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Biohit
Lists including Biohit
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




